XBIT Stock Earnings: XBiotech Reported Results for Q2 2024
XBiotech Q2 2024 Results: XBiotech reported a second-quarter earnings per share of -43 cents, with no revenue generated during the quarter.
InvestorPlace Earnings Automation: InvestorPlace Earnings utilizes automated data from TradeSmith to quickly deliver key financial metrics and comparisons to analyst estimates without human intervention.
Trade with 70% Backtested Accuracy
Analyst Views on XBIT
About XBIT
About the author
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
Investigation into XBiotech: Pomerantz LLP is investigating claims of securities fraud against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis program due to irregularities in trial results, which led to a significant drop in stock price.
Pomerantz LLP's Background: The firm, known for its expertise in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has secured substantial damages for class members over the years.
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws
Investigation Announcement: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis drug candidate, Natrunix, due to irregularities in a recent clinical trial.
Stock Impact: The announcement led to a significant drop in XBiotech's stock price, falling over 29% from $6.38 to $4.50 per share as concerns about the study's findings and implications for future research arose.
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws
Investigation Announcement: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis drug candidate, Natrunix, due to irregularities and failure to meet primary study endpoints.
Stock Impact: The announcement led to a significant drop in XBiotech's stock price, falling over 29% from $6.38 to $4.50 per share as concerns about the integrity of clinical trial data emerged.
XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
Investigation Announcement: The Schall Law Firm is investigating XBiotech Inc. for potential violations of securities laws related to misleading statements and undisclosed information following the pause of its rheumatoid arthritis drug candidate, Natrunix.
Shareholder Rights: Shareholders who have suffered losses are encouraged to contact the Schall Law Firm for a free consultation regarding their rights and potential participation in the investigation.
XBiotech Appoints Renowned Scientist to Board of Directors
XBiotech Board Appointment: XBiotech Inc. has appointed Dr. Tak W. Mak, a renowned immunologist, to its Board of Directors, aiming to enhance leadership and innovation in the oncology therapeutics field.
Company Performance Overview: XBiotech's current market cap is $124.7M with a year-to-date price performance of 2.25% and a strong buy consensus rating based on average trading volume of 61,993 shares.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
Investigation Announcement: Pomerantz LLP is investigating claims of securities fraud against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis program due to failed results, leading to a significant drop in stock price.
Firm Background: Pomerantz LLP, a prominent law firm specializing in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has achieved substantial damages awards for class members.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
Investigation into XBiotech: Pomerantz LLP is investigating claims of securities fraud against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis program due to irregularities in trial results, which led to a significant drop in stock price.
Pomerantz LLP's Background: The firm, known for its expertise in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has secured substantial damages for class members over the years.
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws
Investigation Announcement: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis drug candidate, Natrunix, due to irregularities in a recent clinical trial.
Stock Impact: The announcement led to a significant drop in XBiotech's stock price, falling over 29% from $6.38 to $4.50 per share as concerns about the study's findings and implications for future research arose.
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws
Investigation Announcement: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis drug candidate, Natrunix, due to irregularities and failure to meet primary study endpoints.
Stock Impact: The announcement led to a significant drop in XBiotech's stock price, falling over 29% from $6.38 to $4.50 per share as concerns about the integrity of clinical trial data emerged.
XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
Investigation Announcement: The Schall Law Firm is investigating XBiotech Inc. for potential violations of securities laws related to misleading statements and undisclosed information following the pause of its rheumatoid arthritis drug candidate, Natrunix.
Shareholder Rights: Shareholders who have suffered losses are encouraged to contact the Schall Law Firm for a free consultation regarding their rights and potential participation in the investigation.
XBiotech Appoints Renowned Scientist to Board of Directors
XBiotech Board Appointment: XBiotech Inc. has appointed Dr. Tak W. Mak, a renowned immunologist, to its Board of Directors, aiming to enhance leadership and innovation in the oncology therapeutics field.
Company Performance Overview: XBiotech's current market cap is $124.7M with a year-to-date price performance of 2.25% and a strong buy consensus rating based on average trading volume of 61,993 shares.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
Investigation Announcement: Pomerantz LLP is investigating claims of securities fraud against XBiotech Inc. following the company's announcement of pausing its rheumatoid arthritis program due to failed results, leading to a significant drop in stock price.
Firm Background: Pomerantz LLP, a prominent law firm specializing in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has achieved substantial damages awards for class members.
